BioInvent to Initiate P-I/IIa Study with BI-1206 in Combination with Merck’s Keytruda (pembrolizumab) for Solid Tumors

 BioInvent to Initiate P-I/IIa Study with BI-1206 in Combination with Merck’s Keytruda (pembrolizumab) for Solid Tumors

BioInvent to Initiate P-I/IIa Study with BI-1206 in Combination with Merck’s Keytruda (pembrolizumab) for Solid Tumors

Shots:

  • In July’2019, Bioinvent reports the FDA’s acceptance of its IND application of BI-1206 + Keytruda combination therapy based on the preclinical data demonstrating that BI-1206 enhances anti-tumor immune responses in patients with solid tumors
  • BioInvent will evaluate the combination therapy in P-I/IIa study in patients with an advanced solid tumor, prior treated with anti-PD1 or anti-PD-L1 antibodies
  • BioInvent’s BI-1206 is an anti- FcγRllB antibodies, currently being investigated in non-Hodgkin lymphoma and chronic lymphocytic leukemia and has received FDA’s OD designation for mantle cell lymphoma in 2019

Click here to­ read full press release/ article | Ref: BioInvent | Image: Nordic Life Science Insight

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post